Group 1 - The 31st China International Medical Instrument and Equipment Exhibition and Technology Exchange Conference will be held from August 15 to August 17, 2025, in Beijing, focusing on AI technology applications in healthcare [1] - The seminar titled "Walking with AI: Health Silk Road AI Empowerment" aims to break down medical resource barriers and promote efficient collaboration among medical resources across regions and countries [2] - The "Xihe No. 1" medical model, developed by Peking University Third Hospital and other partners, has been trained on 1 million real clinical cases, achieving over 100 billion parameters and high accuracy in medical knowledge [3][4] Group 2 - The "Xihe No. 1" model is built on rigorous clinical data, ensuring low error rates and high compliance, which is crucial for its commercial application [4] - The model addresses significant issues in cardiovascular disease diagnosis, such as high misdiagnosis rates and delays in treatment, by providing a core research system focused on clinical needs [5] - The company aims to create an AI + healthcare ecosystem that spans various fields, including omics research and drug development, while also exploring AI-enabled hardware products [6] Group 3 - The company, Tianjin TEDA Biomedical Engineering Co., Ltd., is committed to enhancing global healthcare through AI and has established a strong innovation capability in medical data platform construction and resource collaboration [8] - A recent partnership with Shenzhen Computing Science Research Institute aims to improve data quality and analysis for AI medical model optimization [8] - The company anticipates serving over 100 million patients within three years and aims to establish a global AI collaboration network for shared medical wisdom [9]

Group 1 - The 31st China International Medical Instrument and Equipment Exhibition and Technical Exchange Conference will be held in Beijing from August 15 to August 17, 2025, featuring a seminar on AI in healthcare [1] - The seminar aims to leverage AI technology to create a "Health Silk Road," breaking down barriers in medical resource allocation and enhancing the efficiency of healthcare services across regions [2] - Multiple initiatives were launched during the seminar, including the establishment of a global children's early diagnosis and treatment AI innovation ecosystem, contributing to the construction of the "Health Silk Road" [2] Group 2 - The "Xihe No. 1" medical model, developed by Peking University Third Hospital and other partners, has been a focal point, utilizing 1 million real clinical cases and featuring over 100 billion parameters [3] - The model's training data comes from 18 medical institutions, ensuring high accuracy and compliance, with a medical knowledge coverage rate of 98% and precision rate exceeding 90% [4] - The model aims to address high misdiagnosis rates in cardiovascular diseases and improve diagnostic efficiency in primary care settings [5] Group 3 - The company is building an AI + healthcare ecosystem that encompasses data, models, and clinical applications, focusing on rapid translation of research outcomes into practical applications [6] - The company is also exploring AI-enabled hardware products to meet healthcare service demands, indicating a broadening of its service offerings [6] - The company has formed strategic partnerships to enhance data quality and application in AI medical models, aiming to serve over 100 million patients within three years [8][9]

Group 1 - The 31st China International Medical Instrument and Equipment Exhibition and Technical Exchange Conference will be held in Beijing from August 15 to August 17, 2025, featuring a seminar on AI in healthcare [1] - The seminar aims to leverage AI technology to create a "Health Silk Road," breaking down barriers in medical resource allocation and enhancing the efficiency of healthcare services across regions [2] - Multiple initiatives were launched during the seminar, including the establishment of a global children's early diagnosis and treatment AI innovation ecosystem, contributing to the construction of the "Health Silk Road" [2] Group 2 - The "Xihe No. 1" medical model, developed by Peking University Third Hospital and other partners, has been highlighted, featuring over 100 billion parameters and a 98% coverage rate of medical knowledge [3] - The model's training data is sourced from 18 medical institutions, ensuring high accuracy and compliance, with a reported error rate of less than 10% [4] - The model addresses significant issues in cardiovascular disease diagnosis, where traditional methods have high misdiagnosis rates [5] Group 3 - The company is focused on building an AI + healthcare ecosystem that spans various fields, including omics research and drug development, to accelerate the translation of research outcomes [6] - The company is also exploring AI-enabled hardware products to meet healthcare service demands [6] - The company aims to serve over 100 million patients within three years and establish a global AI collaboration network for shared medical wisdom [9] Group 4 - The company, Tianjin TEDA Biomedical Engineering Co., Ltd., is committed to optimizing medical resource allocation through AI technology [8] - The company has formed strategic partnerships to enhance data quality and application in AI medical models [8] - The company plans to continue its exploration in the AI + healthcare sector, collaborating with various stakeholders to improve healthcare access and quality [9]

採納日期：二零二五年[•]月[•]日 姓名： 孫莉 職務： 董事 警告：此文件的內容並無獲香港任何監管機構審閱。務請 閣下就獎勵之要約謹慎行 事。如 閣下對此文件的內容有任何疑問，請尋求獨立專業意見。 股份獎勵計劃 本人孫莉，天津泰達生物醫學工程股份有限公司董事，謹此確認，隨附之股份獎勵計劃 規則已由本公司股東於二零二五年[•]月[•]日舉行之股東大會上以通過普通決議案方式 獲本公司批准，且下文所示日期即為該規則所界定之「採納日期」： 1 索引 天津泰達生物醫學工程股份有限公司 Tianjin TEDA Biomedical Engineering Company Limited （於中華人民共和國註冊成立的股份有限公 司） （股份代 號：8189） | 段落 | 標題 | 頁碼 | | --- | --- | --- | | 1. | 釋義及詮釋 | 3 | | 2. | 目的、管理及期限 | 11 | | 3. | 授出獎勵 | 13 | | 4. | 回撥機制 | 19 | | 5. | 獎勵歸屬 | 20 | | 6. | 獎勵失效 | 24 | | 7. | 獎勵取消 | 26 | | 8. | 計 ...

天津泰達生物醫學工程股份有限公司 Tianjin TEDA Biomedical Engineering Company Limited （於中華人民共和國註冊成立的股份有限公 司） （股份代 號：8189） 香港聯合交易所有限公司對本公佈之內容概不負責，對其準確性或完整性亦不發表任 何聲明，並明確表示概不就因本公佈全部或任何部分內容而產生或因倚賴該等內容而 引致之任何損失承擔任何責任。 董事會會議通告 天津泰達生物醫學工程股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈將於2025 年8月29日（星期五）上午十一時正在中華人民共和國（「中國」）天津市天津經濟技術開發 區第四大街80號天大科技園A2座第9層舉行董事會會議，以處理下列事項： 承董事會命 天津泰達生物醫學工程股份有限公司 主席 孫莉 中國天津 2025年8月13日 1 (1) 審閱及批准本公司及其附屬公司（統稱「本集團」）截至2025年6月30日止之半年度未 經審核綜合財務報表； (2) 批准將於香港聯合交易所有限公司GEM網站刊載之本集團截至2025年6月30日止 之半年度業績草擬公佈； (3) 考慮派付中期股息（如有）； (4) 考慮暫 ...

地址為 乃天津泰達生物醫學工程股份有限公司（「本公司」）股本中每股面值人民幣0.10元的股份 股 （附註2） 的登記持有人，茲委任 （附註3及8） 股東特別大會主席或 地址為 為本人╱吾等的代表，代表本人╱吾等出席本公司將於二零二五年八月二十九日（星期五）上午十時正在中華人民共和國天津 市天津開發區第四大街80號天大科技園第A2座9樓舉行的股東特別大會（或其任何續會）以考慮並酌情通過召開股東特別大會的 通告所載決議案，並於股東特別大會（或其任何續會）按下列指示，就有關決議案以本人╱吾等名義代表本人╱吾等投票，或倘 無有關指示，則本人╱吾等的代表可酌情投票。 | 1. | 批准採納本公司之股份獎勵計劃 | | | | --- | --- | --- | --- | | 2. | 普通決議案 批准採納服務提供者分項限額（定義見本公司股份獎勵計劃） | （附註4） 贊成 | （附註4） 反對 | 天津泰達生物醫學工程股份有限公司 Tianjin TEDA Biomedical Engineering Company Limited （於中華人民共和國註冊成立的股份有限公 司） （股份代 號：8189） 股東特別大會 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本通告全部或任何部分內 容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 天津泰達生物醫學工程股份有限公司 Tianjin TEDA Biomedical Engineering Company Limited （於中華人民共和國註冊成立的股份有限公 司） （股份代 號：8189） 股東特別大會通告 茲通告天津泰達生物醫學工程股份有限公司（「本公司」）謹訂於二零二五年八月二十九 日（星期五）上午十時正假座中華人民共和國（「中國」）天津市天津開發區第四大街80號 天大科技園第A2座9樓舉行股東特別大會（「股東特別大會」），以審議並酌情通過下列作 為本公司普通決議案之決議案： 普通決議案 考慮及批准下列決議案為普通決議案（不論是否予以修訂）： 1 「動議， (a) 待香港聯合交易所有限公司批准H股（因根據本公司股份獎勵計劃（「股份獎 勵計劃」）（其規則載於已提呈股東特別大會並由大會主席簽署以供識別之標有 「 A 」字樣的文件）將予授出的獎勵股份歸屬而可能發行及配發）上市及買賣 後 ...

此乃要件 請即處理 閣下如對本通函的任何方面或應採取的行動有任何疑問，應諮詢 閣下之持牌證券交易商或其他註冊 證券交易商、銀行經理、律師、專業會計師或其他專業顧問。 本通函並不構成收購、購買或認購本公司證券之邀請或要約。 閣下如已將名下的天津泰達生物醫學工程股份有限公司（「本公司」）股份全部出售或轉讓，應立即將本 通函連同隨附代表委任表格送交買主或承讓人或經手出售或轉讓的銀行、持牌證券交易商或其他代理 商，以便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司（「聯交所」）對本通函的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表明概不對因本通函全部或任何部分內容而產生或因倚賴該 等內容而引致的任何損失承擔責任。 天津泰達生物醫學工程股份有限公司 Tianjin TEDA Biomedical Engineering Company Limited （於中華人民共和國註冊成立的股份有限公 司） （股份代 號：8189） (1)採納股份獎勵計劃； 及 (2)股東特別大會通告 本公司謹訂於二零二五年八月二十九日（星期五）上午十時正假座中華人民共和國天津市天津開發區第 四大街80號天大 ...

Core Viewpoint - The company is enhancing its AI medical model business through a strategic partnership with Shenzhen Computing Science Research Institute, focusing on high-quality medical data for training and application [1][2] Group 1: Partnership and Collaboration - The company’s subsidiary, Shenzhen Yishuzhengcheng Technology Co., Ltd., has signed an ecological cooperation agreement with Shenzhen Computing Science Research Institute [1] - The collaboration aims to leverage each party's resources, talent, and technological advantages in database, data quality, and data analysis [1][2] Group 2: AI Medical Model Development - The company is actively developing AI medical models, which require high-quality, secure, and available medical big data as core support [1] - Medical data includes diverse forms such as medical records, imaging, and test reports, necessitating precise data cleaning and annotation [1] Group 3: Strategic Goals - The board believes that the partnership will create a closed-loop ecosystem of "data governance + model iteration + scenario implementation" [2] - This integration will enable the company to provide comprehensive data services, including data cleaning, intelligent analysis, and customized model training for various clients [2] - High-quality data and precise analytical capabilities are expected to accelerate the optimization and commercialization of the company's AI medical models, enhancing its core competitiveness in the AI healthcare sector [2]

Core Viewpoint - The company has signed an ecological cooperation agreement with Shenzhen Computing Science Research Institute to enhance its AI medical model business through collaboration in data quality and analysis [1][2] Group 1: Strategic Cooperation - The agreement aims to leverage the advanced technologies developed by the Shenzhen Computing Science Research Institute in database systems, data quality systems, and data analysis systems [2] - The collaboration will create a closed-loop ecosystem of "data governance + model iteration + scenario implementation" [2] - This partnership is expected to provide comprehensive data services, including data cleaning, intelligent analysis, and customized model training for clients in the healthcare sector, government departments, and industry AI applications [2] Group 2: AI Medical Model Development - The company is focusing on the development of AI medical models, which require high-quality, secure, and available medical big data as core support [1] - The medical data encompasses various forms such as medical records, imaging, and laboratory reports, necessitating high precision in data cleaning and labeling [1] - The collaboration is anticipated to accelerate the optimization and commercialization of the company's AI medical models, enhancing its core competitiveness in the AI healthcare sector [2]